Featured in Vitiligo
Weekly Featured
Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo?
Discover this week's featured video and expert opinion
Latest Vitiligo Videos
Featured CME on Vitiligo
0.5 Credit
Click to save this course
Vitiligo
CME
Reshaping the Routine With JAK Inhibition in Vitiligo Care: An Online Activity
Release Date
April 6, 2026
0.25 Credit
Click to save this course
Vitiligo
CME
DermDash: Vitiligo Spotlight: A Closer Look at JAK Inhibitors
Release Date
December 3, 2025
0.5 Credit
Click to save this course
Vitiligo
CME
Viable Strategies for Using JAK Inhibitors in Vitiligo
Release Date
July 15, 2025
0.75 Credit
Click to save this course
Vitiligo
CME
Vitiligo Pearls and the Patient Conversation: Insights for PAs and NPs: An Online Activity
Release Date
June 26, 2024
Vitiligo Episodes to Explore
Episode 131
Pearls from “The Pearl”: A Time Capsule of Knowledge & Experience with Vitiligo
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, sits down with Pearl Grimes, MD, to discuss the...
Episode 116
Patience, Persistence, and Positivity: A New Era in Vitiligo Treatment
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by a world expert in pigmentation, Seemal...
Vitiligo Case Study
Vitiligo
A Case of Nonsegmental Vitiligo on the Face and Hands Treated With Combination Topical JAK Inhibitor and Phototherapy
Case authors Mavra Masood, MD, Jennifer Creasor, BSN, and Iltefat Hamzavi, MD, present a case of a 74-year-old female with persistent generalized vitiligo...
Show moreVitiligo News & Research
International Severity Criteria Developed for Vitiligo
Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress
By Elana Gotkine (HealthDay News) | | April 09, 2026
AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo
Benefits include total and facial repigmentation in patients 12 years and older versus placebo
By Lori Solomon (HealthDay News) | | April 09, 2026
JAK Inhibitor + 308-nm Excimer Laser Treatment Promising for Pediatric Vitiligo
Significantly higher repigmentation rates seen for pediatric patients receiving JAK inhibitor versus topical tacrolimus therapy combined with 308-nm excimer laser
By Dermsquared Editorial Team | | March 17, 2026